Design Therapeutics, Inc.
For the period ended Nov 4, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 4, 2026 · Filed Nov 4, 2026
Use the contents to explore the available documents and sections.
DSGN$10.21+5.6%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · (in thousands)
(in thousands)
| September 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| (unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash, cash equivalents and investment securities | $208,608 | $219,845 |
| Prepaid expenses and other current assets | 5,355 | 3,939 |
| Total current assets | 213,963 | 223,784 |
| Property and equipment, net | 573 | 981 |
| Right-of-use asset | 2,272 | 1,438 |
| Total assets | $216,808 | $226,203 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $2,078 | $2,312 |
| Accrued expenses and other current liabilities | 10,675 | 10,743 |
| Total current liabilities | 12,753 | 13,055 |
| Operating lease liability | 1,859 | 645 |
| Total liabilities | 14,612 | 13,700 |
| Total stockholders’ equity | 202,196 | 212,503 |
| Total liabilities and stockholders’ equity | $216,808 | $226,203 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.